|Mr. Peter Jonathan Butterfield||CEO & Exec. Director||978.91k||N/A||1976|
|Mr. Andrew Timothy Franklin||CFO & Exec. Director||417.2k||N/A||1966|
|Mr. Stephen Kidner||Chief Scientific Affairs & Operations Officer||N/A||N/A||N/A|
|Mr. Alex Duggan||Chief Commercial & Corp. Devel. Officer||N/A||N/A||N/A|
|Ms. Janice Timberlake||Chief People & Infrastructure Officer||N/A||N/A||N/A|
|Mr. Steve Lobb||Head of Hydromol||N/A||N/A||N/A|
|Mr. David Hope||Head of Secondary Care||N/A||N/A||N/A|
|Mr. Rajiv Ghidiyal||Head of APAC, EMEA & Americas||N/A||N/A||N/A|
|Mr. Karim Husny||Head of International||N/A||N/A||N/A|
|Chris Delafield||Global Marketing Head of Kelo-Cote||N/A||N/A||N/A|
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Alliance Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.